In vitro pharmacological actions of sinomenine on the smooth muscle and the endothelial cell activity in rat aorta

Life Sciences
Seiichiro Nishida, Hiroyasu Satoh

Abstract

Vasodilating actions of sinomenine were examined using rat aorta ring strips. Sinomenine (0.1 to 100 microM) dilated norepinephrine (NE, 5 microM)-induced vasoconstriction in a concentration-dependent manner reaching 68.8+/-5.1% (n=6, P<0.01) at a concentration of 100 microM. Sinomenine (100 microM) also attenuated KCl (60 mM) and phorbol 12, 13-dibutyrate (PDB, a protein kinase C, PK-C, activator, 300 nM)-induced vasoconstriction by 86.9+/-8.5% (n=6, P<0.01) and 49.9+/-9.8% (n=6, P<0.01), respectively. Pretreatment with nicardipine (a Ca2+ channel antagonist), staurosporine (a PK-C inhibitor), NG-monomethyl-L-arginine acetate (L-NMMA, a nitric oxide, NO, synthesis inhibitor), and indomethacin (a cyclooxygenase inhibitor) were carried out. Nicardipine (0.1 microM) led to a significant decrease in the vasodilating potential of sinomenine (at 100 microM, 68.8+/-5.1% vs. 35.5+/-6.9%; n=5, P<0.001). Pretreatment with staurosporine (30 nM) reduced sinomenine-associated vasodilation from 68.8+/-5.1% to 49.5+/-7.7% (n=5, P<0.001), and L-NMMA (100 microM) and indomethacin (10 microM), to 25.3+/-2.3% (n=5, P<0.001) and to 37.1+/-9.3% (n=5, P<0.001), respectively. The responses were almost similar to the results without endothelium. Ther...Continue Reading

References

Jan 1, 1987·The Journal of Membrane Biology·H FichtnerM Kohlhardt
Aug 1, 1994·International Journal of Immunopharmacology·L LiuV Kaever
Oct 1, 1996·International Journal of Immunopharmacology·L LiuR W Kinne
Apr 2, 1998·General Pharmacology·H Satoh, N Sperelakis
Apr 17, 2003·Transplantation·Walter MarkRaimund Margreiter
Apr 23, 2005·The American Journal of Chinese Medicine·Wei-Tien ChangZuo-Hui Shao

❮ Previous
Next ❯

Citations

Oct 30, 2007·Evidence-based Complementary and Alternative Medicine : ECAM·Seiichiro Nishida, Hiroyasu Satoh
Aug 24, 2007·Clinical and Experimental Pharmacology & Physiology·Ping-Ying LeeJuei-Tang Cheng
Jan 1, 2009·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Hiroyasu Satoh
Nov 15, 2008·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Seiichiro Nishida, Hiroyasu Satoh
Jan 15, 2011·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Hiroyasu Satoh, Seiichiro Nishida
Dec 24, 2013·World Journal of Gastroenterology : WJG·Jing WangShi Qiu
Oct 8, 2013·Bioscience, Biotechnology, and Biochemistry·Ki Hyun KimKang Ro Lee
Jul 11, 2012·Pharmaceutical Biology·Xiang-Xiang ZhaoLu-Ping Qin
Apr 29, 2014·Journal of Ethnopharmacology·Camille DesgrouasEvelyne Ollivier
Feb 6, 2007·Bioorganic & Medicinal Chemistry Letters·Hongyan DuYalin Tang
Sep 12, 2015·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Hiroyasu Satoh, Seiichiro Nishida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

© 2022 Meta ULC. All rights reserved